Respirology
Expert Brief 1: All-Cause Mortality with Triple Therapy in COPD
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.
This program has received an unrestricted educational grant or in-kind support from GSK.
DURATION
15 min
PROFESSION
Physician
# OF CREDITS
0.3
ACCREDITATION
Mainpro+
EXPIRY DATE
2023-09-30
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.
This program has received an unrestricted educational grant or in-kind support from GSK.
Faculty
John Axler, MD, LMCC, CCFP, FCFP
Andre Belanger, MD, CFPC
Jeff Habert, MD, CCFP, FCFP
Sol Stern, Bsc, MD, MCFP
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Determine the role of inhaled corticosteroid therapy in patients with COPD
- Review the impact of COPD triple therapy (LAMA/LABA/ICS) on all-cause mortality
Accreditation
This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.3 Mainpro+ credits.
This program is developed in collaboration with ICEBM.